symbicort turbuhaler 4,5+160 mikrog/dosis inhalationspulver
astrazeneca a/s - budesonid, formoterolfumarat dihydrat - inhalationspulver - 4,5+160 mikrog/dosis
oxis turbuhaler 9 mikrogram/dosis inhalationspulver
astrazeneca a/s - formoterolfumarat dihydrat - inhalationspulver - 9 mikrogram/dosis
spirocort 0,25 mg/ml inhalationsvæske til nebulisator, suspension
astrazeneca a/s - budesonid - inhalationsvæske til nebulisator, suspension - 0,25 mg/ml
spirocort turbuhaler 100 mikrogram/dosis inhalationspulver
astrazeneca a/s - budesonid - inhalationspulver - 100 mikrogram/dosis
spirocort turbuhaler 200 mikrogram/dosis inhalationspulver
astrazeneca a/s - budesonid - inhalationspulver - 200 mikrogram/dosis
spirocort turbuhaler 400 mikrogram/dosis inhalationspulver
astrazeneca a/s - budesonid - inhalationspulver - 400 mikrogram/dosis
zoladex 3,6 mg implantat, fyldt injektionssprøjte
astrazeneca a/s - goserelinacetat - implantat, fyldt injektionssprøjte - 3,6 mg
imfinzi
astrazeneca ab - durvalumab - carcinom, ikke-småcellet lunge - antineoplastiske midler - non-small cell lung cancer (nsclc)imfinzi as monotherapy is indicated for the treatment of locally advanced, unresectable non small cell lung cancer (nsclc) in adults whose tumours express pd-l1 on ≥ 1% of tumour cells and whose disease has not progressed following platinum based chemoradiation therapy (see section 5. imfinzi in combination with tremelimumab and platinum-based chemotherapy is indicated for the first-line treatment of adults with metastatic nsclc with no sensitising egfr mutations or alk positive mutations. small cell lung cancer (sclc)imfinzi in combination with etoposide and either carboplatin or cisplatin is indicated for the first-line treatment of adults with extensive-stage small cell lung cancer (es-sclc). biliary tract cancer (btc)imfinzi in combination with gemcitabine and cisplatin is indicated for the first line treatment of adults with unresectable or metastatic biliary tract cancer (btc). hepatocellular carcinoma (hcc)imfinzi in combination with tremelimumab is indicated for the first line treatment of adults with advanced or unresectable hepatocellular carcinoma (hcc).
bricanyl 0,5 mg/ml injektionsvæske, opløsning
astrazeneca a/s - terbutalinsulfat - injektionsvæske, opløsning - 0,5 mg/ml
bricanyl 0,3 mg/ml oral opløsning
astrazeneca a/s - terbutalinsulfat - oral opløsning - 0,3 mg/ml